Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by ArTelO Biosciences, Inc. on June 24, 2022. The company is incorporated in Nevada and its common stock (ARTL) and warrants (ARTLW) trade on The Nasdaq Stock Market, LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are provided in this document.
Material Changes and Voting Results
Of the 42,301,013 shares outstanding entitled to vote, 15,733,250 shares (37.19%) were represented, constituting a quorum. The following matters were approved:
- Election of Directors: Seven nominees were re-elected to serve until the 2023 annual meeting. All nominees received majority support, though Gregory D. Gorgas received the highest number of "Against" votes (635,335) among the directors.
- Say-on-Pay Vote: Stockholders approved the advisory vote on executive compensation for the year ended December 31, 2021, with 4,121,598 votes "For" and 998,904 "Against."
- Say-on-Pay Frequency: Stockholders approved holding the Say-on-Pay vote every three years (2,456,016 votes) rather than annually or biennially.
- Stock Issuance Approval: Stockholders approved the potential issuance and sale of 20% or more of the Company's Common Stock to Lincoln Park Capital Fund, LLC at an average price less than the Minimum Price pursuant to a Purchase Agreement.
- Auditor Ratification: The appointment of Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified with 15,112,289 votes "For."
Guidance, Outlook, and Risks
This filing does not provide management commentary on future guidance, outlook, or specific operational risks. The primary contingency noted is the authorization to issue a significant portion of common stock (20% or more) to Lincoln Park Capital Fund, LLC, which may result in dilution to existing shareholders depending on the execution of the Purchase Agreement.
Key Facts for Investor Verification
- Verify the terms of the Purchase Agreement with Lincoln Park Capital Fund, LLC, specifically the "Minimum Price" and the conditions under which the 20%+ issuance will occur.
- Review the proxy statement for the 2022 Annual Meeting to understand the specific compensation details approved in the Say-on-Pay vote.
- Monitor the company's capital structure for potential dilution resulting from the approved stock issuance to Lincoln Park Capital Fund, LLC.
- Confirm the re-election of the board members, noting the specific vote counts for each director.